Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 2/20 | 0.65 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14310605 | 0.83 | VHL (0.69) | VHLP2RX7HCAR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2828248 | 0.81 | VHL (0.67) | VHLP2RX7HCAR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL10189863 | 0.81 | VHL (0.55) | VHLP2RX7ALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL6251 | 0.80 | VHL (0.60) | VHLP2RX7HCAR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL23866627 | 0.80 | VHL (0.65) | VHLP2RX7HCAR2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL314902 | 0.80 | VHL (0.65) | VHLP2RX7HCAR2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1375734 | 0.79 | VHL (0.58) | VHLP2RX7HCAR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL21661625 | 0.79 | VHL (1.00) | VHLP2RX7ALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL23331085 | 0.79 | VHL (0.63) | VHLP2RX7HCAR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3452361 | 0.78 | VHL (0.58) | VHLP2RX7SMN1; SMN2EPHX2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | VHL 2018/4885P2RX7 2186/4885HCAR2 80/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | VHL 961/4885P2RX7 288/4885HCAR2 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.